+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H2, 2019

  • ID: 4629788
  • Clinical Trials
  • December 2019
  • Region: Global
  • 796 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Arcturus Therapeutics Ltd
  • Eli Lilly and Co
  • Johnson & Johnson
  • KemPharm Inc
  • Neos Therapeutics Inc
  • Novartis AG
  • MORE
Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H2, 2019

Summary

The clinical trial report, “Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H2, 2019“ provides an overview of Attention Deficit Hyperactivity Disorder (ADHD) clinical trials scenario. This report provides top line data relating to the clinical trials on Attention Deficit Hyperactivity Disorder (ADHD)Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Arcturus Therapeutics Ltd
  • Eli Lilly and Co
  • Johnson & Johnson
  • KemPharm Inc
  • Neos Therapeutics Inc
  • Novartis AG
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Attention Deficit Hyperactivity Disorder (ADHD)
  • Nov 11, 2019: Supernus submits New Drug Application for SPN-812 for the treatment of ADHD
  • Nov 05, 2019: Supernus Pharmaceuticals announces data from phase III study of SPN-810 for treatment of Impulsive Aggression (IA) in ADHD patients
  • Nov 04, 2019: Ironshore to present data from a pivotal trial of JORNAY PM (methylphenidate HCl) CII at the 31st Annual International Conference on ADHD
  • Oct 22, 2019: KemPharm presents study highlighting patient-friendly dosing properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting
  • Oct 16, 2019: Ironshore Pharmaceuticals to present data at the 66th Annual AACAP Meeting
  • Oct 04, 2019: Oryzon reveals positive data from anti-aggression drug vafidemstat
  • Sep 23, 2019: ORYZON presents new data on vafidemstat
  • Clinical Trial Profile Snapshots
Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About the Author
  • Contact Us
  • Source
List of Tables
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Region, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, North America, Top Countries, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2019*
  • Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, G7 Countries (%), 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, E7 Countries (%), 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Phase, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
List of Figures
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Region (%), 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2019*
  • Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, G7 Countries (%), 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, E7 Countries (%), 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Phase (%), 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
  • Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Takeda Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • Johnson & Johnson
  • Novartis AG
  • QPS Holdings LLC
  • Neos Therapeutics Inc
  • Supernus Pharmaceuticals Inc
  • KemPharm Inc
  • Arcturus Therapeutics Ltd
  • Mundipharma International Ltd
Note: Product cover images may vary from those shown
Adroll
adroll